Synonym
SC 51316; SC-51316; SC51316;
IUPAC/Chemical Name
4-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,5-dibutyl-2,4-dihydro-3H-1,2,4-triazol-3-one
InChi Key
STODEQQYGGTXOS-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H29N7O/c1-3-5-11-22-27-31(16-6-4-2)24(32)30(22)17-18-12-14-19(15-13-18)20-9-7-8-10-21(20)23-25-28-29-26-23/h7-10,12-15H,3-6,11,16-17H2,1-2H3,(H,25,26,28,29)
SMILES Code
O=C1N(CCCC)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
431.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Olins GM, Smits GJ, Koepke JP, Huang HC, Reitz DB, Manning RE, Blaine EH. In vivo pharmacology of SC-51316, a nonpeptidic angiotensin II receptor antagonist. Am J Hypertens. 1993 Jul;6(7 Pt 1):619-25. PubMed PMID: 8398003.
2: Olins GM, Corpus VM, McMahon EG, Palomo MA, Schuh JR, Blehm DJ, Huang HC, Reitz DB, Manning RE, Blaine EH. In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316. J Pharmacol Exp Ther. 1992 Jun;261(3):1037-43. PubMed PMID: 1602371.
3: Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol. 1998 Mar;274(3 Pt 2):F580-6. PubMed PMID: 9530275.
4: Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int. 1995 May;47(5):1285-94. PubMed PMID: 7637258.
5: Huang HC, Reitz DB, Chamberlain TS, Olins GM, Corpus VM, McMahon EG, Palomo MA, Koepke JP, Smits GJ, McGraw DE, et al. Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists. J Med Chem. 1993 Jul 23;36(15):2172-81. PubMed PMID: 8340920.
6: Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest. 1993 Apr;91(4):1453-8. PubMed PMID: 8473494; PubMed Central PMCID: PMC288120.
7: Klahr S, Ishidoya S, Morrissey J. Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis. 1995 Jul;26(1):141-6. Review. PubMed PMID: 7611245.
